The resolution and minutes of the 2025 Annual General Meeting (AGM) of Hau Giang Pharmaceutical Joint Stock Company (DHG) were approved. During the meeting, shareholders discussed and approved several important decisions regarding the company’s business development direction for 2025 and long-term investment plans. Accordingly, DHG will continue to expand production, enhance competitiveness, and improve technology to meet market demands. Clear financial targets for 2025 have been set with expectations for revenue and profit growth. The meeting also discussed dividend distribution plans and capital increase strategies for sustainable growth. The resolution addressed the election of additional members to the Board of Directors and strategic directions for developing new products.
Leave a Reply